Literature DB >> 29681202

Quality of life in psoriatic arthritis.

Tania Gudu1, Laure Gossec2.   

Abstract

INTRODUCTION: Psoriatic arthritis (PsA) is a multi-organ chronic inflammatory disease which impacts patients both physically and psychologically. The highest priority for patients goes to pain relief, but also to ability to function and participate in social life, fatigue, and psychological distress. Areas covered: In the present article, we will review current knowledge on impairments of health-related quality of life related to PsA, as well as patient priorities and patient-reported outcome measures such as the PsA Impact of Disease or the PsA Quality of Life questionnaires. The impact of PsA appears to be very broad, covering all aspects of life, i.e. activities and participation, physical and emotional aspects, but also domains such as fatigue, coping or sleep disturbance. Some of these aspects which are important for PsA patients have been included in the recently updated PsA Core Domain Set to be reported in clinical studies. Expert commentary: A better understanding of quality of life issues faced by patients with PsA could improve patient-physician communication and ultimately, quality of care. QoL is altered in PsA due both to the physical impact, but also the psychological impact of this disease. Several scores are available to better assess these aspects of PsA.

Entities:  

Keywords:  Assessment; disease activity; fatigue; patient-reported outcomes; psoriatic arthritis; psychological distress; quality of life

Mesh:

Year:  2018        PMID: 29681202     DOI: 10.1080/1744666X.2018.1468252

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  39 in total

Review 1.  Does current evidence on disease-modifying antirheumatic drugs for psoriatic arthritis reinforce an effect on radiographic progression? Results from a systematic review and meta-analysis.

Authors:  Mariana Garcia-Leal; Mayra A Reyes-Soto; Ivan Hernandez-Galarza; Neri A Alvarez-Villalobos; Dionicio A Galarza-Delgado; Diana E Flores-Alvarado
Journal:  Clin Rheumatol       Date:  2021-02-12       Impact factor: 2.980

Review 2.  Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review.

Authors:  Jordi Gratacós Masmitjà; Carlos M González Fernández; Susana Gómez Castro; Francisco José Rebollo Laserna
Journal:  Adv Ther       Date:  2020-12-17       Impact factor: 3.845

Review 3.  Disease activity indices in psoriatic arthritis: current and evolving concepts.

Authors:  Chrysoula G Gialouri; George E Fragoulis
Journal:  Clin Rheumatol       Date:  2021-05-18       Impact factor: 2.980

4.  The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study.

Authors:  Panagiotis Athanassiou; Anastasios Kotrotsios; Ioannis Kallitsakis; Andreas Bounas; Theodoros Dimitroulas; Alexandros Garyfallos; Maria G Tektonidou; Giorgos Vosvotekas; Achilleas Livieratos; Evangelia Petrikkou; Gkikas Katsifis
Journal:  Qual Life Res       Date:  2021-11-28       Impact factor: 4.147

5.  Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.

Authors:  Ana-Maria Orbai; Laura C Coates; Atul Deodhar; Philip S Helliwell; Christopher T Ritchlin; Evan Leibowitz; Alexa P Kollmeier; Elizabeth C Hsia; Xie L Xu; Shihong Sheng; Yusang Jiang; Yan Liu; Chenglong Han
Journal:  Patient       Date:  2022-06-30       Impact factor: 3.481

6.  A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study.

Authors:  Christian Dejaco; Thomas Mueller; Omid Zamani; Ulrike Kurtz; Stefan Egger; Johannes Resch-Passini; Anna Totzauer; Babak Yazdani-Biuki; Thomas Schwingenschloegl; Peter Peichl; Angelika Kraus; Gerhard W Naerr
Journal:  Front Med (Lausanne)       Date:  2022-06-02

7.  A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab.

Authors:  Vincenzo Venerito; Giuseppe Lopalco; Anna Abbruzzese; Sergio Colella; Maria Morrone; Sabina Tangaro; Florenzo Iannone
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

8.  Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.

Authors:  Philip J Mease; Iain B McInnes; Lai-Shan Tam; Kiefer Eaton; Steve Peterson; Agata Schubert; Soumya D Chakravarty; Anna Parackal; Chetan S Karyekar; Sandhya Nair; Wolf-Henning Boehncke; Christopher Ritchlin
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

9.  Relationship Between Skin Shame, Psychological Distress and Quality of Life in Patients with Psoriasis: a Pilot Study.

Authors:  Donja Homayoon; Michaela Hiebler-Ragger; Moritz Zenker; Wolfgang Weger; Human Unterrainer; Elisabeth Aberer
Journal:  Acta Derm Venereol       Date:  2020-07-02       Impact factor: 3.875

10.  Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib.

Authors:  Kurt de Vlam; Alexis Ogdie; Andrew G Bushmakin; Joseph C Cappelleri; Roy Fleischmann; Peter C Taylor; Valderilio Azevedo; Lara Fallon; John Woolcott; Philip J Mease
Journal:  RMD Open       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.